| Literature DB >> 36051483 |
Di Hu1, Zenan Lin2, Junhong Jiang2, Pan Li3, Zhehuan Zhang1, Chenhao Yang1.
Abstract
Purpose: To identify the potential key genes and molecular pathways associated with keratoconus and allergic disease.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36051483 PMCID: PMC9427295 DOI: 10.1155/2022/4740141
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1Overall strategy used for the identification of potential key genes and molecular pathways associated with keratoconus and allergic disease.
Top nineteen GO biological processes of TMGs.
| Process | Genes in query set | Total genes in genome | Corrected hypergeometric | Genes |
|---|---|---|---|---|
| Positive regulation of gene expression | 24 | 516 | 6.21 | VIM, FN1, BMP2, MMP8, OCLN, CTNNB1, CEBPB, EDA, KIT, TGFB1, EGF, NGF, NOS3, SP1, CD34, GSN, IFNG, TNF, VEGFA, IL1A, IL6, TNC, ATM, IL4 |
| Positive regulation of phosphatidylinositol 3-kinase signaling | 11 | 81 | 5.39 | CAT, SELP, HGF, FN1, KIT, EGF, LEP, TNF, VEGFA, TGFB2, MYOC |
| Response to hypoxia | 13 | 159 | 1.98 | CAT, BMP2, LEP, MMP2, TNF, VEGFA, TGFB2, LTA, IL1A, VCAM1, PLAU, ATM, NOS2 |
| Positive regulation of MAPK cascade | 13 | 172 | 4.05 | HGF, BMP2, MMP8, CTNNB1, KIT, EGF, LEP, ALK, ITGA1, TNF, VEGFA, IL6, SOD1 |
| Collagen catabolic process | 8 | 38 | 8.58 | MMP1, MMP8, MMP13, MMP10, MMP9, CTSB, MMP2, MMP3 |
| Immune response | 18 | 477 | 2.18 | IL10, HLA-B, MS4A2, CD40LG, IL1RN, CEBPB, EDA, FASLG, IL2, IFNG, IL16, HLA-A, TNF, LTA, IL1A, IL6, B2M, IL4 |
| Inflammatory response | 17 | 413 | 2.18 | SELP, ITGB2, BMP2, ITCH, LYZ, MS4A2, CD40LG, IL1RN, CEBPB, KIT, TGFB1, TNF, IL1A, IL6, ITGAL, CD44, NOS2 |
| Extracellular matrix disassembly | 8 | 48 | 3.96 | MMP1, MMP8, MMP13, MMP10, MMP9, GSN, MMP2, MMP3 |
| Response to lipopolysaccharide | 11 | 161 | 2.30 | SELP, IL10, CEBPB, FASLG, NOS3, TNF, LTA, BCR, IL1A, VCAM1, NOS2 |
| Cellular response to UV-A | 5 | 11 | 3.38 | MMP1, MMP9, MMP2, MMP3, TIMP1 |
| Positive regulation of tyrosine phosphorylation of STAT protein | 8 | 68 | 5.16 | KIT, LEP, IL2, IFNG, TNF, VEGFA, IL6, IL4 |
| Negative regulation of apoptotic process | 17 | 529 | 5.17 | CAT, FLNA, HGF, IL10, ITCH, CTNNB1, CD40LG, LEP, MMP9, IL2, TNF, VEGFA, IL6, CD44, SOD1, IL4, TIMP1 |
| Cell-matrix adhesion | 9 | 103 | 6.37 | ITGB2, FN1, CTNNB1, EDA, ITGA1, CD34, VCAM1, ITGAL, CD44 |
| Leukocyte cell-cell adhesion | 6 | 30 | 1.48 | SELP, ITGB2, CD40LG, ICAM1, VCAM1, ITGAL |
| Positive regulation of cell migration | 12 | 259 | 1.92 | HGF, BMP2, KIT, TGFB1, EGF, MMP9, MMP2, VEGFA, PLAU, ATM, MYOC, IL4 |
| Extracellular matrix organization | 10 | 171 | 3.41 | MMP1, ITGB2, MMP8, MMP13, MMP10, MMP9, MMP2, TNF, MMP3, ITGAL |
| Positive regulation of cell population proliferation | 16 | 548 | 4.23 | RPS4X, FN1, CTNNB1, KIT, TGFB1, FASLG, EGF, LEP, IL2, IFNG, VEGFA, TGFB2, IL6, TNC, IL4, TIMP1 |
| Cellular response to lipopolysaccharide | 10 | 182 | 5.47 | VIM, IL10, CD68, CEBPB, TNF, BCR, IL1A, IL6, NOS2, B2M |
| Positive regulation of interleukin-6 production | 8 | 99 | 6.03 | MMP8, LEP, IFNG, IL16, TNF, IL1A, IL6, NOS2 |
Top twenty-four KEGG pathways of TMGs.
| Process | Genes in query set | Total genes in genome | Corrected hypergeometric | Genes |
|---|---|---|---|---|
| Malaria | 13 | 50 | 6.57 | SELP, HGF, ITGB2, IL10, CD40LG, TGFB1, IFNG, TNF, ICAM1, TGFB2, IL6, VCAM1, ITGAL |
| Allograft rejection | 9 | 37 | 3.17 | IL10, HLA-B, CD40LG, FASLG, IL2, IFNG, HLA-A, TNF, IL4 |
| Rheumatoid arthritis | 12 | 91 | 3.17 | MMP1, ITGB2, TGFB1, IFNG, TNF, ICAM1, VEGFA, MMP3, TGFB2, IL1A, IL6, ITGAL |
| Cytokine-cytokine receptor interaction | 18 | 293 | 3.17 | IL10, BMP2, CD40LG, IL1RN, EDA, TGFB1, FASLG, NGF, LEP, IL2, IFNG, IL16, TNF, TGFB2, LTA, IL1A, IL6, IL4 |
| Pathways in cancer | 21 | 531 | 8.07 | MMP1, HGF, FN1, BMP2, CTNNB1, KIT, TGFB1, FASLG, EGF, MMP9, ALK, SP1, IL2, IFNG, MMP2, VEGFA, TGFB2, BCR, IL6, NOS2, IL4 |
| AGE-RAGE signaling pathway in diabetic complications | 11 | 100 | 8.07 | FN1, TGFB1, NOS3, MMP2, TNF, ICAM1, VEGFA, TGFB2, IL1A, IL6, VCAM1 |
| Graft-versus-host disease | 8 | 42 | 2.39 | HLA-B, FASLG, IL2, IFNG, HLA-A, TNF, IL1A, IL6 |
| Type I diabetes mellitus | 8 | 43 | 2.55 | HLA-B, FASLG, IL2, IFNG, HLA-A, TNF, LTA, IL1A |
| Inflammatory bowel disease | 9 | 65 | 3.05 | IL10, TGFB1, IL2, IFNG, TNF, TGFB2, IL1A, IL6, IL4 |
| Proteoglycans in cancer | 13 | 205 | 9.11 | FLNA, HGF, FN1, CTNNB1, TGFB1, FASLG, MMP9, MMP2, TNF, VEGFA, TGFB2, PLAU, CD44 |
| Leishmaniasis | 9 | 76 | 1.04 | ITGB2, IL10, TGFB1, IFNG, TNF, TGFB2, IL1A, NOS2, IL4 |
| African trypanosomiasis | 7 | 36 | 1.44 | IL10, FASLG, IFNG, TNF, ICAM1, IL6, VCAM1 |
| Human T cell leukemia virus 1 infection | 13 | 222 | 1.84 | ITGB2, HLA-B, TGFB1, IL2, HLA-A, TNF, ICAM1, TGFB2, LTA, IL6, ITGAL, ATM, B2M |
| IL-17 signaling pathway | 9 | 94 | 5.45 | MMP1, MMP13, CEBPB, MMP9, IFNG, TNF, MMP3, IL6, IL4 |
| Amoebiasis | 9 | 101 | 8.96 | ITGB2, IL10, FN1, TGFB1, IFNG, TNF, TGFB2, IL6, NOS2 |
| Chagas disease | 9 | 101 | 8.96 | IL10, TGFB1, FASLG, IL2, IFNG, TNF, TGFB2, IL6, NOS2 |
| Fluid shear stress and atherosclerosis | 10 | 139 | 1.17 | CTNNB1, NOS3, MMP9, IFNG, MMP2, TNF, ICAM1, VEGFA, IL1A, VCAM1 |
| Autoimmune thyroid disease | 7 | 52 | 1.39 | IL10, HLA-B, CD40LG, FASLG, IL2, HLA-A, IL4 |
| TNF signaling pathway | 9 | 112 | 1.80 | ITCH, CEBPB, MMP9, TNF, ICAM1, MMP3, LTA, IL6, VCAM1 |
| Cell adhesion molecules | 10 | 148 | 1.80 | SELP, ITGB2, HLA-B, OCLN, CD40LG, CD34, HLA-A, ICAM1, VCAM1, ITGAL |
| Lipid and atherosclerosis | 11 | 214 | 6.35 | MMP1, SELP, CD40LG, FASLG, NOS3, MMP9, TNF, ICAM1, MMP3, IL6, VCAM1 |
| Hematopoietic cell lineage | 8 | 98 | 7.16 | KIT, ITGA1, CD34, TNF, IL1A, IL6, CD44, IL4 |
| NF-kappa B signaling pathway | 8 | 102 | 8.92 | CD40LG, EDA, TNF, ICAM1, LTA, VCAM1, PLAU, ATM |
| Tuberculosis | 10 | 179 | 8.92 | ITGB2, IL10, CEBPB, TGFB1, IFNG, TNF, TGFB2, IL1A, IL6, NOS2 |
Figure 2The protein–protein interaction network of the 59 target TMGs.
Figure 3(a) The protein–protein interaction (PPI) network of the target TMGs was visualized using Cytoscape. (b–d) The three modules were obtained from PPI network using MCODE: (b) module 1; (c) module 2; (d) module 3.
Figure 4(a) Overlapping TMGs among the four topological cytoHubba methods including MCC, MNC, DMNC, and EPC. (b) Functions and pathways of the hub genes were visualized using ClueGO. (c) Enriched GO terms and KEGG pathways. (d) Distribution of the functions and pathways among the hub genes. Only the most significant term in the group was labeled. Representative enriched pathway (P < 0.05) interactions among the hub genes.
Figure 5Top 40 significantly enriched GO terms in module 1.
Figure 6(a) The significantly enriched GO terms in module 2. (b) The significantly enriched KEGG pathways in module 2.
Figure 7(a) The significantly enriched GO terms in module 3. (b) The significantly enriched KEGG pathways in module 3.
Figure 8Top 40 significantly enriched KEGG pathways in module 1.